Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

"CRISPR DNA Editing illustration"

Biotech

Nine things to know about Sangamo Therapeutics and its first-in-human genome editing study

By Adam Feuerstein

CAR-T Conference

Health

How to pay for CAR-T: A conversation with health policy expert Peter Bach

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

advertisement

Minds

Biotech

A scrappy crew of biotechs is working on a new wave of schizophrenia medicines

By Meghana Keshavan

advertisement

D.C. Insight IMAGE

Opinions Plus

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

By Elizabeth Cooney

The Readout LOUD

LISTEN: A lesson in startup jargon, pharma’s bare Alzheimer’s cupboard, and the cost of CAR-T

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Antiva CEO Gail Maderis

Biotech

A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it

By Rebecca Robbins

ACT UP 1989

Health

As Alzheimer’s drug developers give up on today’s patients, where is the outrage?

By Sharon Begley

advertisement

China biotech flag

Biotech

The Nasdaq’s newest ETF invites investors to bet on Chinese biopharma

By Rebecca Robbins

advertisement

STAT SPOTLIGHT

Biotech

Startup Spotlight: Flagship Pioneering’s Sigilon gets a new CEO

By Kate Sheridan

Alnylam RNAi

Biotech

A landmark drug approval shows RNAi’s promise — even as it hints at its limits

By Kate Sheridan

John and Megan Crowley

Biotech

Amicus’ rare disease drug, once indefinitely delayed, wins FDA approval

By Damian Garde

Empty pipeline

Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

Alnylam headquarters

Biotech

FDA approves first-ever RNAi-based therapy

By Kate Sheridan

The Readout LOUD

LISTEN: Insider trading goes to Washington, online bloodshed over fake meat, & doctors vs. fund managers

By Damian Garde and Rebecca Robbins

Dr. Steven Rosenberg

In the Lab

After 30 years, an immunotherapy to rival CAR-T finally nears the clinic

By Sharon Begley

Vertex

Business

Vertex gets approval to treat toddlers with cystic fibrosis drug

By Jonathan Saltzman — Boston Globe

MORE Red Blood Cells

Biotech

Wall Street is writing off Spark’s hemophilia gene therapy. Clinicians are not

By Damian Garde

Biotech

Musician-scientist Manny Simons and Akouos seek way to treat a gene-based hearing loss

By Jonathan Saltzman — Boston Globe

Red Blood Cells

Biotech

Spark’s gene therapy data answer some burning questions — and raise a few more

By Damian Garde

An illustration of a human head created out of bacteria.

Health

As microbiome testing firms proliferate, so do questions about their claims

By Leah Shaffer

Biotech

The FDA is poised to approve the first-ever drug that mutes disease-causing genes

By Kate Sheridan

CAR-T Cell Therapies

Biotech

Regeneron and Bluebird Bio strike a deal to discover and develop cancer treatments

By Ed Silverman

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

An image of a woman's hands who has been affected by Thalidomide.

In the Lab

Scientists find a new clue about how thalidomide caused devastating birth defects

By Megan Thielking

Immunotherapy scans

Politics

To pay for cutting-edge CAR-T therapies, Medicare plays it safe, for now

By Ike Swetlitz

The Readout LOUD

LISTEN: Biotech’s sellers market, Sanofi’s second act, and literally climbing Mt. Everest

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

A microscope image of frozen baker's yeast.

In the Lab

Assembling yeast chromosomes like Legos has a serious goal: safe lab-made creatures

By Sharon Begley

Paula Soteropoulos, CEO of Akcea Therapeutics.

Biotech

Two Akcea drugs are about to hit the market — but are they already too late?

By Kate Sheridan